Takara Holdings Inc.: Notice Regarding the Succession of Subsidiary Takara Bio Inc.’s GMP Cell Processing Contract Manufacturing Business

Overview of the Transaction

Takara Holdings Inc. resolved to transfer the GMP cell processing contract manufacturing business of consolidated subsidiary Takara Bio Inc. to S-RACMO by an absorption-type split. The effective date is scheduled to be January 1, 2027, and the split method will be a simplified absorption-type split. In conjunction with the succession, Takara Bio will focus resources on core modalities such as nucleic acids/plasmids, proteins/enzymes, and viral vectors. The company will improve the efficiency of management resources through workforce reductions while securing employment opportunities, obtaining consideration for the transfer, and selling equipment.

Outlook and Impact

There will be no changes to Takara Bio's name, location, business description, capital, or fiscal year-end after the absorption-type split, and the impact on the Company's consolidated results is expected to be minor. Rights and obligations to be succeeded will transfer as stipulated in the absorption-type split agreement. S-RACMO is scheduled to obtain shareholder meeting approval before the day preceding the absorption-type split.